Paratek Pharmaceuticals’ Omadacycline Shines in Phase 3

Paratek Pharmaceuticals’ omadacycline prevailed in a Phase 3 study evaluating the drug in patients with acute bacterial skin and skin structure infections.

In a trial pitting the candidate against linezolid, omadacycline met the FDA’s primary efficacy endpoint of early clinical response at 48 to 72 hours. Additionally, the treatment met the EMA’s co-primary efficacy endpoints for post-treatment evaluation.

This is the first of two pivotal Phase 3 trials, according to the company.